DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

By Snigdha Gupta, Principal Analyst

This Market Event Analysis provides an overview of the accelerated FDA approval for GSK’s anti-BCMA therapy BLENREP based on positive results reported from the DREAMM-2 trial.

Multiple efficacious therapies are available for the treatment of multiple myeloma, setting the bar high for emerging therapies seeking to enter this competitive space. Therapies targeting the BCMA antigen are in pivotal clinical trials for the treatment of this disease. BLENREP has become the first anti-BCMA therapy to secure a position in the treatment algorithm of multiple myeloma (relapsed or refractory setting). As per DRG’s Multiple Myeloma Disease Landscape and Forecast (G7) report, this approval was a highly anticipated event for 2020 in the multiple myeloma treatment landscape.

This analysis is being offered to you as a valued client, we hope that you find it useful. Please let us know if you’d like to engage with our expert analysts.

Download Here